Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

Presentation TCT Abstracts Posters 2018

Outcomes of Preoperative Bridging with Intravenous Antiplatelet Therapy in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention

Presenter: Bassel Bou Dargham

September 25, 2018

Presentation JIM 2018

Clinical Case: Management of Long-Term DAPT

Presenter: Ugo Limbruno

February 23, 2018

Presentation TTT 2018

Prolonged DAPT should be Standard of Care Post PCI?

Presenter: Tan Huay Cheem

January 14, 2018

Presentation Cardiovascular Interventions 2016

DAPT after Stenting: How Short When Needed and How Long When Tolerated?

Presenter: Dean J. Kereiakes

November 10, 2016

Presentation CCVVC 2016

Optimal Duration of DAPT: Update on DAPT Guidelines

Presenter: Roxana Mehran

June 16, 2016

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Advertisement

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Outcomes of Preoperative Bridging with Intravenous Antiplatelet Therapy in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention

Clinical Case: Management of Long-Term DAPT

Prolonged DAPT should be Standard of Care Post PCI?

DAPT after Stenting: How Short When Needed and How Long When Tolerated?

Optimal Duration of DAPT: Update on DAPT Guidelines

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content